Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Silvio Inzucchi MD
Silvio E. Inzucchi MD Editor-in-Chief
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
See All Experts
featured
Published in Diabetes

Journal Scan / Research · February 20, 2023

Efficacy and Safety of Empagliflozin vs Placebo and Linagliptin vs Placebo in Young Patients With Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Ishita Jindal MD

The Lancet Diabetes & Endocrinology
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
Lancet Diabetes Endocrinol 2023 Feb 01;[EPub Ahead of Print], LM Laffel, T Danne, GJ Klingensmith, WV Tamborlane, S Willi, P Zeitler, D Neubacher, J Marquard

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated